The efficacy of pronase premedication in capsule endoscopy

Effects of premedication with pronase for image quality and examination time of capsule endoscopy in stomach: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-DPD-16009556

Enrollment

Unknown

Registered

2016-10-23

Start date

2016-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of digestive tract

Interventions

Gold Standard:

Index test:

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who need to undergo capsule endoscopy examination; 2. Patients who can take drugs orally; 3. Aged between 18 and 70 years.

Exclusion criteria

Exclusion criteria: 1. Known or suspected gastrointestinal obstruction, stenosis, fistula or diverticulum; 2. Dysphagia diseases; 3. Pregnant women and infants; 4. A variety of acute enteritis, severe ischemic disease and radiation colitis, such as bacterial dysentery, acute period of ulcerative colitis, especially the outbreak; 5. With congestive heart failure or severe ventilation dysfunction; 6. Allergic to polymer materials or allergic to drugs that may be required for testing; 7. Critically ill, difficult to ensure the safety of the process; 8. Mental illness patients; 9. Will be subjected to MRI within 7 days after swallowing the capsules; 10. The doctor considers that there are any other causes that are not suitable for such an examinatiom.

Design outcomes

Primary

Measure	Time frame
Quality of capsule endoscopy image;Examination time;	—

Countries

China

Contacts

Public ContactSun Siyu

Shengjing Hospital of China Medical University

sunsy@sj-hospital.org+86 18940251329

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026